Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes

Samah Hayek (), Yatir Ben-shlomo, Noa Dagan, Ben Y. Reis, Noam Barda, Eldad Kepten, Alina Roitman, Shachar Shapira, Shlomit Yaron, Ran D. Balicer, Doron Netzer and Alon Peretz
Additional contact information
Samah Hayek: Clalit Health Services
Yatir Ben-shlomo: Clalit Health Services
Noa Dagan: Clalit Health Services
Ben Y. Reis: The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute
Noam Barda: Ben Gurion University
Eldad Kepten: Clalit Health Services
Alina Roitman: Clalit Health Services
Shachar Shapira: Israel Defense Forces Medical Corps
Shlomit Yaron: Clalit Health Services
Ran D. Balicer: Clalit Health Services
Doron Netzer: Clalit Health Services
Alon Peretz: Clalit Health Services

Nature Communications, 2022, vol. 13, issue 1, 1-5

Abstract: Abstract REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare organization to determine the real-world effectiveness of REGEN-COV treatment against COVID-19-related hospitalization, severe disease, and death. We compared patients infected with Delta variant and treated with REGEN-COV (n = 289) to those infected but not-treated with REGEN-COV (n = 1,296). Demographic and clinical characteristics were used to match patients and for further adjustment as part of the C0x model. Estimated treatment effectiveness was defined as one minus the hazard ratio. Treatment effectiveness of REGEN-COV was 56.4% (95% CI: 23.7–75.1%) in preventing COVID-19 hospitalization, 59.2% (95% CI: 19.9–79.2%) in preventing severe COVID-19, and 93.5% (95% CI: 52.1–99.1%) in preventing COVID-19 death in the 28 days after treatment. In conclusion, REGEN-COV was effective in reducing the risk of severe sequelae in high-risk COVID-19 patients.

Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32253-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32253-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32253-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().